Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2018 | Pages:
87 | Publisher: Grand View Research
Industry: Healthcare | Report Format: Electronic (PDF)
The global acute repetitive seizures market size is expected to reach USD 3.19 billion by 2025, according to a new report by Grand View Research, Inc. The report also states that the market will expand at a strong CAGR of 47.8% during the forecast period. Rise in the number of initiatives to increase the awareness about epilepsy is the major factor driving the market. The market is currently led by generic drugs which mainly include oral benzodiazepines (diazepam and lorazepam). Rectal diazepam is the only approved drug for use in U.S. and buccal midazolam in European Union. Other drugs, such as diazepam (oral and intramuscular), midazolam (buccal, intranasal, intramuscular), lorazepam (oral, intranasal, sublingual), and progesterone are majorly used off label. The market is expected to be consolidated with few major companies and high market share. Furthermore, in an attempt to curb healthcare expenditure, governments are making continuous efforts to reduce hospital stays and on-site treatment costs via outpatient care models, such as clinic and home healthcare. Emerging economies like India and China, are increasingly implementing such healthcare reform, which is expected to propel the growth of acute repetitive seizures market. There are several routes of drug administration; out of which, nasal route is the most preferred over others, such as buccal, rectal, and parenteral. The buccal route is preferred by caregivers and parents for children suffering from pediatric seizures since medication can be administered even outside the hospital. Further key findings from the study suggest: • Global acute repetitive seizures market size was estimated at USD 140.5 million in 2017 and is expected to register a CAGR of 47.8% over the forecast period • Diastat rectal gel was the dominant product segment in 2017 due to efficacy of the route of administration and affordability of the product • USL-261 is expected to witness a lucrative CAGR over the forecast period. USL-21 has an edge over the other drugs owing to its superior clinical profile and positive phase III results • North America held the largest share in 2017 due to factors, such as growing initiatives for raising awareness about epilepsy and seizures • Germany is anticipated to witness lucrative growth over the next decade owing to technological advancements in scientific, clinical, and medical fields • Some of the key companies in the market are UCB S.A.; Neurelis, Inc.; and Alexza Pharmaceuticals, Inc. These companies are likely to dominate the market and gain maximum share over the forecast period
Table of Contents
Chapter 1 Methodology and Scope
1.1 Research Methodology
1.2 Research Scope and Assumptions
1.3 List to Data Sources
Chapter 2 Executive Summary
Chapter 3 Market Variables, Trends & Scope
3.1 Market Segmentation
3.2 Acute Repetitive Seizures Market
3.3 Market Driver Analysis
3.3.1 Presence of strong pipeline and increasing initiatives for R&D
3.3.2 Presence of treatment gap in adequate seizure control
3.3.3 Other drivers
3.4 Market restraint Analysis
3.4.1 Cost of treatment
3.5 Penetration Mapping
3.6 Caregiver's perception on route of administration
3.7 Importance of having no sedation as a side effect
3.8 Opportunity Analysis
Chapter 4 Acute Repetitive Seizures: Product Outlook
4.1 Acute repetitive seizures Market: Product Movement Analysis
4.2 USL-261
4.2.1 USL-261 market, 2013 - 2025 (USD Million)
4.3 NRL-1
4.3.1 NRL-1 market, 2013 - 2025 (USD Million)
4.4 AZ-002
4.4.1 AZ-002 market, 2013 - 2025 (USD Million)
4.5 Diastat Rectal Gel
4.5.1 Diastat Rectal Gel market, 2013 - 2025 (USD Million)
4.6 Others
4.6.1 Other acute repetitive seizures market, 2013 - 2025 (USD Million
Chapter 5 Acute repetitive seizures Market: Regional Estimates & Trend Analysis
5.1 Acute repetitive seizures market share by region, 2016 & 2025
5.2 North America
5.2.1 North America acute repetitve seizures market, 2013 - 2025 (USD Million)
5.2.1.1 U.S.
5.2.1.2 U.S. acute repetitve seizures market, 2013 - 2025 (USD Million)
5.2.1.2 Canada
5.2.1.2 Canada acute repetitve seizures market, 2013 - 2025 (USD Million)
5.3 Europe
5.3.1 Europe acute repetitve seizures market, 2013 - 2025 (USD Million)
5.3.1.1 Germany
5.3.1.2 Germany acute repetitve seizures market, 2013 - 2025 (USD Million)
5.3.1.3 U.K.
5.3.1.4 U.K. acute repetitve seizures market, 2013 - 2025 (USD Million)
5.4 Rest of World
5.4.1 Rest of World acute repetitve seizures market, 2013 - 2025 (USD Million)
Chapter 6 Competitive Landscape
6.1 Strategy Framework
6.2 Company Profiles
6.2.1 UCB S.A. Belgium
6.2.1.1 Company overview
6.2.1.2 Financial performance
6.2.1.3 Product benchmarking
6.2.1.4 Strategic initiatives
6.2.2 Neurelis
6.2.2.1 Company overview
6.2.2.2 Financial performance
6.2.2.3 Product benchmarking
6.2.2.4 Strategic initiatives
6.2.3 Valeant Pharmaceuticals North America LLC.
6.2.3.1 Company overview
6.2.3.2 Financial performance
6.2.3.3 Product benchmarking
6.2.3.4 Strategic initiatives
6.2.4 Alexza Pharmaceuticals
6.2.4.1 Company overview
6.2.4.2 Product benchmarking
6.2.4.3 Strategic initiatives
6.2.5 VERITON PHARMA
6.2.5.1 Company overview
6.2.5.2 Financial performance
6.2.5.3 Product benchmarking
6.2.5.4 Strategic initiatives
List of Tables Table 1 Acute Repetitive Seizures Pipeline, 2018 Table 2 Country share estimation Table 3 North America acute repetitive seizures market, by product, 2013 - 2025 (USD Million) Table 4 U.S. acute repetitive seizures market, by product, 2013 - 2025 (USD Million) Table 5 Canada acute repetitive seizures market, by product, 2013 - 2025 (USD Million) Table 6 Europe acute repetitive seizures market, by product, 2013 - 2025 (USD Million) Table 7 Germany acute repetitive seizures market, by product, 2013 - 2025 (USD Million) Table 8 U.K. acute repetitive seizures market, by product, 2013 - 2025 (USD Million) Table 9 Rest of World acute repetitive seizures market, by product, 2013 - 2025 (USD Million)
List of Figures Fig. 1 Market summary Fig. 2 Market research process Fig. 3 Information procurement Fig. 4 Value chain-based sizing & forecasting Fig. 5 QFD modelling for market share assessment Fig. 6 Market trends & outlook Fig. 7 Market segmentation & scope Fig. 8 Global acute repetitive seizures market, 2013 - 2025 (USD Million) Fig. 9 Market driver relevance analysis (Current & future impact) Fig. 10 Market restrain relevance analysis (Current & future impact) Fig. 11 Penetration & growth prospect mapping Fig. 12 SWOT Analysis, By Factor (political & legal, economic and technological) Fig. 13 Porter's Five Forces Analysis Fig. 14 Acute repetitive seizures market product outlook key takeaways Fig. 15 Acute repetitive seizures market: Product movement analysis Fig. 16 Global USL-261 market, 2013 - 2025 (USD Million) Fig. 17 Global Neurelis-1 market, 2013 - 2025 (usd million) Fig. 18 Global AZ-002 market, 2013 - 2025 (USD Million) Fig. 19 Global diastat rectal gel market, 2013 - 2025 (USD Million) Fig. 20 Others market, 2013 - 2025 (USD Million) Fig. 21 Regional market place: Key takeaways Fig. 22 Acute repetitive seizures market: Regional movement analysis Fig. 23 North America acute repetitive seizures market, 2013 - 2025 (USD Million) Fig. 24 U.S. acute repetitive seizures market, 2013 - 2025 (USD Million) Fig. 25 Canada acute repetitive seizures market, 2013 - 2025 (USD Million) Fig. 26 Europe acute repetitive seizures market, 2013 - 2025 (USD Million) Fig. 27 Germany acute repetitive seizures market, 2013- 2025 (USD Million) Fig. 28 U.K. acute repetitive seizures market, 2013 - 2025 (USD Million) Fig. 29 Rest of World acute repetitive seizures market, 2013 - 2025 (USD Million) Fig. 30 Strategy framework
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
